Clinical Trial Update: StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating StrataXRT to prevent radiation dermatitis in pediatric patients undergoing brain or spinal irradiation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasm
• Central Nervous System Sarcoma
• Ependymoma
• Glioma
• Malignant Intracranial Germ Cell Tumor
• Medulloblastoma
• Pineoblastoma

Drugs mentioned

• StrataXRT

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Central Nervous System Sarcoma, Ependymoma | Phase 1 | Status: WITHDRAWN